|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��ԭ��,ɳ�� |
|
��ԭ��Ƹ�Ⱦ |
|
��� |
|
���� |
|
���� |
| ��������������� | |
|
��Ӱ |
|
����� |
|
��ʤ�� |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
ɳ����ԭ���Ⱦ�ķ������ơ�����������½�չ
��Ӱ, �����, ��ʤ��
���ľ�ҽ��ѧ��һ����ҽԺƤ���� ���� 710032
ɳ����ԭ���Ⱦ�ѳ�Ϊһ����ṫ���������⡣������ֳ��ɳ����ԭ���Ⱦ�ѳ�Ϊ������Դ�������֮һ,����������ֲ���֢����һ���˽�ɳ����ԭ���Ⱦ�ķ�������,���������١����С�����ļ�ⷽ��,������ɳ����ԭ���Ⱦ�ķ��Ρ��ع���ɳ����ԭ���Ⱦ�ķ������ơ���������Ʒ�����½�չ��
[2] Shaw JH, Grund VR, Durling L, et al. Expression of genes encoding Th1 cell-activating cytokines and lymphoid homing chemokines by chlamydia-pulsed dendritic cells correlates with protective immunizing efficac y. Infect Immun, 2001, 69:4667-4672.
[3] Witkin SS. Imnunological aspects of genital chlamydia infections.Best Pract Res Clin Obstet Gynaecol, 2002, 16:865-874.
[4] Mardh PA. Influence of infection with Chlamydia trachomatis on pregnancy outcome, infant health and life-long sequelae in infected offspring. Best Pract Res Clin Obstet Gynaecol, 2002, 16:847.
[5] Horner P, Thomas B, Gilroy C, et al. Antibodies to Chlamydia trachomatis heat-shock protein 60 kDa and detection of Mycoplasma genitalium and ureaplasma urealyticum are associated independently with chronic nongonococcal urethritis. Sex Transm Dis, 2003, 30:129.
[6] Baseviciene I, Labanauskas L, Vysniauskaite N. Clinical characteristics and possibilities of early diagnosis of Chlamydia trachomatis infection in adolescent girls. Medicina (Kaunas), 2002, 38:1157.
[7] Bax CJ, Mutsaers JA, Jansen CL, et al. Comparison of serological assays for detection of Chlamydia trachomatis antibodies in different groups of obstetrical and gynecological patients. Clin Diagn Lab Immunol, 2003, 10:174-176.
[8] Watson EJ, Templeton A, Russell I, et al. The accuracy and efficacy of screening tests for Chlamydia traehomatis: a systematic review. J Med Microbiol, 2002, 51:1021-1031.
[9] Witkin SS, Linhares IM. Chlamydia trachomatis in subfertile women undergoing uterine instrumentation: an alternative to direct microbial testing or prophylactic antibiotic treatment. Hum Reprod, 2002, 17:1938-1941.
[10] Persson K. The role of serology, antibiotic susceptibility testing and serovar determination in genital chlamydial infections. Best Pract Res Clin Obstet Gynaecol, 2002, 16:801-814.
[11] Van Der Pol B, Williams JA, Smith NJ, et al. Evaluation of the Digene Hybrid Capture �� Assay with the Rapid Capture System for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol, 2002, 40:3558-3564.
[12] Gaydos CA, Quinn TC, Willis D, et al. Performance of the APTIMA Combo 2 assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens. J Clin Microbiol, 2003, 41:304-309.
[13] Ostergaard L. Microbiological aspects of the diagnosis of Chlamydia trachomatis. Best Pract Res Clin Obstet Gynaeool, 2002, 16:789.
[14] Oakeshott P, Hay P, Hay S, et al. Detection of Chlamydia trachomatis infection in early pregnancy using self-administered vaginal swabs and first pass urines: a cross-sectional community-based survey. Br J Gen Pract, 2002, 52:830-832.
[15] Morre SA, van den Brule AJ, Rozendaal L, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up, Int J STD AIDS, 2002, 13:12-18.
[16] Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc, 1999, 74:613.
[17] Skerk V, Schonwald S, Krhen I, et al. Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother,2002, 14:384-389.
[18] Gomberg MA. Combined treatment of persisting urogenital chlamydia infection with sumamed and interferon alfa. Antibiot Khimioter,2002, 47:12-15.
[19] Fletcher MA. Vaccine candidates in STD. Int J STD AIDS, 2002, 13(Suppl 2) :38-41.
[20] Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccines: strategies and status. BioDrugs, 2002, 16:19-35.
[21] Moore T, Ananaba GA, Bolier J, et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology, 2002,105:213-221.
[22] Lu H, Xing Z, Brunham RC. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J Immunol, 2002,169:6324-6331.